Three stocks to buy for healthy long-term growth

A professional investor tells us where he’d put his money. This week: Ketan Patel, manager of the Amity UK fund at EdenTree Investment Management

The race to develop a commercial vaccine for Covid-19 has brought the healthcare industry into sharp focus. It is a highly diverse and rich area of the market for all types of investors. A growing global population, which is both ageing and ailing, remains a highly supportive long-term backdrop for the sector. The rise of the middle class in emerging markets is another tailwind, with more patients able to afford healthcare. Changes in their dietary habits, meanwhile, will lead to an increase in chronic conditions such as diabetes, autoimmune and cardiovascular diseases.

A sector to suit all investors

The depth and breadth offered by the global healthcare industry is second to none. It includes well-established multinational companies operating in drug research and development, life sciences, diagnostics, distribution, medical technology and animal health. Moreover, the mix of quality, defensive and growth stocks in the healthcare industry should appeal to all types of investors.

The medical-technology subsector contains well-established groups such as Smith & Nephew, which have built high-quality businesses capable of delivering long-term earnings growth. The search for companies that can deliver year on year, so-called compounders, is the Holy Grail for investors with a long-term investment horizon. 

In the mid- and small-cap segments, well-positioned businesses with material exposure to the diagnostics and life sciences sectors include Bioventix, Clinigen, IP Group, Smiths Group, Oxford Instruments and Spectris.

Solid blue-chip income 

Meanwhile, the large-cap pharmaceutical research and development (R&D) giants, such as GlaxoSmithKline, have defensive business models with low leverage, high margins, strong cash-flow generation and sustainable income. It is no surprise that this sector has stood up well during the coronavirus pandemic. What’s more, there has not been a dividend cut in this part of the market for more than two decades (excluding mergers and acquisitions). This remains a big draw at a time when the global dividend landscape has been fractured by cuts, suspensions, cancellations and deferrals. 

Large-cap growth opportunities 

There are also growth opportunities in the large-cap segment, with the likes of AstraZeneca offering highly attractive earnings growth for investors. Long-term investors in AstraZeneca have been well compensated: it has become the most valuable company in the FTSE 100, closely followed by GlaxoSmithKline. Within animal health, a sector forecast to grow by a third to $44bn by 2024, market-leading companies such as Genus and Dechra Pharmaceuticals are set to deliver double-digit earnings growth. 

GlaxoSmithKline (LSE: GSK), AstraZeneca (LSE: AZN) and Smith & Nephew (LSE: SN) are global leaders in their areas and have developed business models with low leverage and high margins, which leads to excellent free cash flow over an extended period of time. Driven by long-cycle macro trends, all three firms look set to continue to deliver for long-term investors – regardless of the macroeconomic environment.

Recommended

Pension dashboard delayed until 2026
Pensions

Pension dashboard delayed until 2026

The deadline for pension schemes to connect to an online pension dashboard, allowing savers to see all their retirement pots in one place, has been pu…
8 Jun 2023
Who is the richest person in the world?
Entrepreneurs

Who is the richest person in the world?

Jeff Bezos, Bill Gates and Elon Musk are among the richest people in the world, but the top spot belongs to someone else.
7 Jun 2023
The building blocks for an income strategy: resilience, growth and diversification
Advertisement Feature

The building blocks for an income strategy: resilience, growth and diversification

Iain Pyle, Investment Manager, Shires Income plc
7 Jun 2023
Saving vs investing: which is better to help you make more money?
Personal finance

Saving vs investing: which is better to help you make more money?

Saving has become a more attractive option with interest rates hitting the highest levels seen in years, but if you’re prepared to take some risk inve…
7 Jun 2023

Most Popular

How much will it cost you to retire early?
Pensions

How much will it cost you to retire early?

The pre-state pension income gap means couples may need an extra £136,000 if they want to retire at 60 – can you afford to retire early?
6 Jun 2023
Best easy access savings accounts – June 2023
Savings

Best easy access savings accounts – June 2023

Rising interest rates have boosted the returns on instant-access savings accounts and we're seeing some of the highest rates seen in years. We look at…
6 Jun 2023
Best debit and credit cards to use while travelling abroad
Personal finance

Best debit and credit cards to use while travelling abroad

If you’re going on holiday or travel abroad regularly, it’s worth knowing what the best card is to avoid hefty fees. We weigh up the charges and any p…
6 Jun 2023